TY - JOUR
T1 - PI3 Kinase Activation and Response to Trastuzumab Therapy
T2 - What's neu with Herceptin Resistance?
AU - Park, Ben Ho
AU - Davidson, Nancy E.
N1 - Funding Information:
Supported by NIH CA 88843.
PY - 2007/10/16
Y1 - 2007/10/16
N2 - Trastuzumab is an established therapy for women with breast cancers that overexpress HER2. Despite its proven benefit in treating breast cancer, not all women derive benefit from this monoclonal antibody, and resistant disease can develop. In this issue of Cancer Cell, Berns et al. present evidence that activation of the PI3 kinase pathway, either via loss of the tumor suppressor PTEN or through oncogenic stimulation of PIK3CA, can mediate trastuzumab resistance. This study extends important work of others and forms the rationale for future investigations combining inhibitors of the PI3 kinase pathway in conjunction with trastuzumab therapy.
AB - Trastuzumab is an established therapy for women with breast cancers that overexpress HER2. Despite its proven benefit in treating breast cancer, not all women derive benefit from this monoclonal antibody, and resistant disease can develop. In this issue of Cancer Cell, Berns et al. present evidence that activation of the PI3 kinase pathway, either via loss of the tumor suppressor PTEN or through oncogenic stimulation of PIK3CA, can mediate trastuzumab resistance. This study extends important work of others and forms the rationale for future investigations combining inhibitors of the PI3 kinase pathway in conjunction with trastuzumab therapy.
UR - http://www.scopus.com/inward/record.url?scp=35148854641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35148854641&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2007.10.004
DO - 10.1016/j.ccr.2007.10.004
M3 - Short survey
C2 - 17936554
AN - SCOPUS:35148854641
SN - 1535-6108
VL - 12
SP - 297
EP - 299
JO - Cancer cell
JF - Cancer cell
IS - 4
ER -